WB result of TAK1 Recombinant Rabbit mAb
Primary antibody: TAK1 Recombinant Rabbit mAb at 1/1000 dilution
Primary antibody incubation conditions: overnight at 4°C
Lane 1: HeLa whole cell lysate 20 µg
Lane 2: HEK-293 whole cell lysate 20 µg
Lane 3: A-431 whole cell lysate 20 µg
Lane 4: A549 whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 65 kDa
Observed MW: 69 kDa
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | TAK1 |
| Location | Nucleus |
| Accession | P49116 |
| Clone Number | S-6525 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu |
| Positive Sample | HeLa, HEK-293, A-431, A549 |
| Predicted Reactivity | Ms, Rt |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
Background
TAK1 (transforming growth factor-β-activated kinase 1, encoded by the MAP3K7 gene) is a widely expressed serine/threonine kinase of the MAP3K family that serves as a core integrating hub of the NF-κB and MAPK signaling pathways, playing key roles in immunity, inflammation, development, and cell survival. Structurally, it contains an N-terminal kinase domain and a C-terminal regulatory domain and requires assembly with TAK1-binding proteins (TAB1, TAB2, etc.) into a complex for efficient activation, a process involving sequential autophosphorylation of multiple activation-loop residues. TAK1 lies downstream of TNF receptor, Toll-like receptor, and IL-1 receptor signaling and regulates the NF-κB and JNK/p38 pathways by activating the IKK complex and MKK4/7 and MKK3/6, respectively. In intestinal epithelial cells, TAK1 maintains barrier integrity by restraining TNFR1-proximal death signaling, whereas in myeloid cells it can amplify inflammatory signals, displaying cell-type- and disease-stage-specific dual functions. In addition, TAK1 acts as a tumor-intrinsic immune checkpoint that protects cancer cells from CD8⁺ T cell- and cytokine-mediated killing. Clinically, gain-of-function mutations in MAP3K7 cause frontometaphyseal dysplasia and cardiospondylocarpofacial syndrome, while different mutation types can also cause developmental abnormalities such as neonatal dilated cardiomyopathy.
Picture
Picture
Western Blot
